Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective motoneuron loss. Although the cause of ALS is unknown, oxidative stress, inflammation, and mitochondrial dysfunction have been identified as important components of its pathogenesis. Peroxisome proliferatorYactivated receptor-F coactivator 1> (PGC-1>) plays a central role in the regulation of mitochondrial metabolism and biogenesis via activation of transcription factors, such as nuclear respiratory factors 1 and 2 and mitochondrial transcription factor A (Tfam). Alterations in PGC-1> expression and function have previously been described in models of Huntington and Alzheimer diseases. Moreover, the protective effects of PGC-1> have been shown in animal models of ALS. Levels of PGC-1> correlate with the number of acetylcholine receptor clusters in muscle. This is of particular interest because neurodegeneration in ALS may be a dyingback process. We investigated mRNA and protein expressions of PGC-1> and PGC-1>Yregulated factors in the spinal cord and muscle tissues of SOD1 G93A ALS mice and in ALS patients. We detected significant alterations in mRNA expression of PGC-1> and downstream factors with their earliest occurrence in muscle tissue. Our data provide evidence for a role of PGC-1> in mitochondrial dysfunction both in the ALS mouse model and in human sporadic ALS that is probably most relevant in the skeletal muscle.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motoneuron disease. It leads to progressive loss of upper and lower motoneurons and subsequent muscle weakness, ultimately resulting in complete paralysis and death caused by respiratory failure within 3 to 5 years (1, 2) . Five percent to 10% of patients have familial forms of ALS (3, 4) that are indistinguishable at the clinical level but share many common pathogenic pathways with the more common sporadic ALS (5) . The discovery of mutations in the superoxide dismutase 1 (SOD1) gene in 10% to 20% of familial ALS patients led to the generation of a transgenic mouse model that overexpresses human mutant SOD1 G93A (6, 7) .
The precise cause for the selective death of motoneurons in ALS is still unclear, but several processes, including oxidative stress, inflammation, and mitochondrial loss and dysfunction, have been implicated in its pathogenesis. Mitochondrial abnormalities have been identified in spinal cord and skeletal muscle tissues of ALS patients (8Y10); these have also been shown to be among the earliest pathological alterations in ALS mouse models (11, 12) .
The transcriptional coactivator peroxisome proliferatorY activated receptor-F coactivator 1> (PGC-1>) has been implicated in energy homeostasis, adaptive thermogenesis, A-oxidation of fatty acids, and glucose metabolism (13, 14) . The PGC-1> regulates mitochondrial metabolism and biogenesis via activation of transcription factors, such as nuclear respiratory factor 1 (NRF-1) and NRF-2. The NRF-1 and NRF-2 are targets of PGC-1> and stimulate the expression of mitochondrial transcription factor A (Tfam), a mitochondrial matrix protein essential for the replication, maintenance, and transcription of mitochondrial DNA (15, 16) . Moreover, it has been shown that PGC-1> protects neuronal cells from oxidative stress, and that this protection is correlated with an increased expression of manganese superoxide dismutase (mnSOD), a reactive oxygen species (ROS)Ydetoxifying enzyme located in mitochondria. The PGC-1> knockout mice exhibit decreased expression of mnSOD. Thus, inactivation of PGC-1> has been implicated in neurodegeneration (17) . Alterations in PGC-1> expression and function have previously been described in Huntington disease (HD) and Alzheimer disease (18Y22). Recent studies have shown that PGC-1> and peroxisome proliferatorsYactivated receptor-F agonists can protect motoneurons and neuromuscular junctions, alter disease progression, and extend lifespan in animal models of ALS (23Y26).
In a model of Duchenne muscular dystrophy, it was shown that PGC-1> plays a role in the neuromuscular junction gene program by coactivation of NRF-2. Moreover, PGC-1> levels were correlated with the number of acetylcholine receptor (AChR) clusters and with mRNA expression of neuromuscular junctionYrelated genes such as utrophin (Utrn) in the skeletal muscle (27) . This is of particular interest in ALS because there is evidence that degeneration of motor end plates occurs before the loss of motoneuron cell somata in the spinal cord and that neurodegeneration in ALS is, therefore, a dying-back process (28Y30).
To understand whether PGC-1> and PGC-1>Yregulated factors play a role in the mitochondrial and metabolic deficits in ALS, we investigated the mRNA and protein expressions of PGC-1> and downstream factors (NRF-1, NRF-2, Tfam, mnSOD) in the spinal cord, muscle, and brown fat tissue of SOD1 G93A ALS mice and nontransgenic controls in presymptomatic, early symptomatic, and late symptomatic disease stages, and in human postmortem brain and spinal cord tissue and muscle biopsies from ALS patients and controls. We also analyzed the expression of AChR? and Utrn in skeletal muscle tissue to detect a potential relation to the loss of motor end plates in ALS.
MATERIALS AND METHODS

Mouse Tissue
Transgenic male mice overexpressing the human SOD1 G93A mutation (strain B6SJLTg [SOD1-G93A]1Gur/J) (high copy number) [7] ) were purchased from the Jackson Laboratory (Bar Harbor, ME) and mated with wild-type female mice. Transgenic progeny were identified by polymerase chain reaction (PCR) amplification of tail DNA first at the age of 4 weeks and also after death to verify the results of the first genotyping. Primer sequences were adopted from Alexander et al (31) and were synthesized by MWG (Ebersberg, Germany) as follows: hSOD1 forward CAT CAG CCC TAA TCC ATC TGA, hSOD1 reverse CGC GAC TAA CAA TCA AAG TGA, and for internal control interleukin 2 forward CTA GGC CAC AGA ATT GAA AGA TCT and interleukin 2 reverse GTA GGT GGA AAT TCT AGC ATC ATC C. All experiments were carried out in accordance with the internationally accepted principles in the care and use of experimental animals, approved by the local Institutional Animal Care and Research Advisory Committee, and permitted by the local government. Mice were housed under controlled conditions in the Central Animal Facility of Hannover Medical School.
For analysis of lumbar spinal cord, muscle tissue (gastrocnemius muscle), and brown fat tissue, animals were killed at 3 different time points: Day 40 = presymptomatic stage; Day 90 = early symptomatic stage; and at disease end stage as defined in Knippenberg et al (32) . Tissue was immediately shock frozen in liquid nitrogen and stored at -80-C. Transgenic mice (n = 3Y9 for quantitative PCR [qPCR], n = 4Y5 for Western blot analysis) were analyzed in comparison with nontransgenic littermates (n = 3Y9 for qPCR, n = 3Y4 for Western blot analysis). Groups were always sex-matched.
Human Tissue
For analysis of spinal cord and motor cortex, postmortem tissue from ALS patients available at autopsies was compared with that of controls (Table) . The ALS patients had a definite diagnosis based on the El Escorial criteria (33) , with signs of upper and lower motor neuron involvement in 3 body regions. Controls had no evidence of neurologic or psychiatric disease. Postmortem intervals ranged from 6 to 34 hours (Table) . Postmortem tissue samples were cut into 1-cm-thick coronal slices, rapidly frozen on dry ice, and stored at j80-C. The primary motor cortex (Brodmann area 4) was first identified macroscopically. In addition, cytoarchitecture was studied on cryostat sections using Nissl staining. Muscle tissue was obtained from diagnostic biopsies, with patients' informed consent and approval of the local ethics committee. All patients of the ALS group developed definite ALS during further follow-up. Muscle biopsy specimens were only used as controls if the histopathologic analysis had not detected any abnormalities. Biopsy tissue was directly snap frozen in liquid N 2 and stored at j80-C.
Spinal 
qRT-PCR
Tissues were mechanically homogenized using a Power Gen 125 device (Thermo Fisher Scientific, Waltham, MA). Homogenization was done in TRIZOL reagent (Invitrogen, Carlsbad, CA), and total RNA was isolated as recommended by the manufacturer. Genomic DNA elimination was done using a DNase-kit (Stratagene, La Jolla, CA). Reverse transcription of total RNA (2Y10 Kg regarding the tissue) was performed using Random Primers (Invitrogen), the SuperScript II Reverse Transcriptase-System (Invitrogen), and RNasin (Stratagene).
For quantification of mRNA expression levels of PGC-1>, NRF-1, NRF-2, Tfam, mnSOD, AChR? and Utrn the SYBR-Green method with Power SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA) was used. Cyclophilin (Ppia) was taken as a reference (housekeeping) gene. Primer pairs were designed by using NCBI primer-blast and were synthesized by MWG as follows: PGC-1> mouse (forward: CAC CGC AAT TCT CCC TTG TA; reverse: TGC GGT ATT CAT CCC TCT TG), NRF-1 mouse (forward: CCT CTG ATG CTT GCG TCG TCT; reverse: TTA CTC TGC TGT GGC TGA TGG), NRF-2 mouse (forward: CGA CGG 
Western Blot Analysis
Tissue was mechanically homogenized with the Power Gen 125 device in radioimmunoprecipitation assay buffer, and concentrations were determined using Protein Assay Reagent A, B, and S (BioRad Laboratories, Hercules, CA), according to the manufacturer's instructions. Protein homogenates (200 Kg of protein) were electrophoresed on sodium dodecyl sulfate polyacrylamide gels and transferred to Immobilon-P Transfer membranes (Millipore, Bedford, MA) by standard procedures. Nonspecific binding sites were blocked with 5% nonfat dry milk (Sucofin, Zeven, Germany) in Tris buffered saline (TBS), and antibodies were diluted in the same buffer. The following antibodies were used: PGC-1> (1:500; Calbiochem-Millipore, Billerica, MA), NRF-1 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), Tfam (1:500; GenWay, San Diego, CA), mnSOD (1:4000; Abcam, Cambridge, MA), AChR? (1:100; Santa Cruz Biotechnology), and anti-A actin (1:2000; Abcam). Primary antibodies were incubated overnight at 4-C. Detection was performed with suitable horseradish peroxidaseYconjugated secondary antibodies (1:500; R&D System, Minneapolis, MN) followed by chemiluminescent substrate (ECL kit; Amersham, Buckingham, UK; or SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Scientific, Rockford, IL), and signals were detected by Chemolumineszenz Imager (Intas Science Instruments, Gottingen, Germany). Membranes were stripped with Glycine HCl and reprobed up to 3 times. Quantification was done by densitometry using ImageJ software. Values were normalized to A-actin.
Immunohistochemistry
Animal tissues from end-stage SOD1 G93A and control animals were fixed after dissection with 4% paraformaldehyde in PBS overnight, cryoprotected in 30% sucrose, and embedded in TissueTek (Sakura Finetek, Zoeterwoude, The Netherlands). Human tissue was directly embedded and fixed before the staining procedure for 5 minutes. Tissue was stored at j80-C after embedding. Twelve-Km-thick tissue sections were cut on a cryostat. Slides were washed in TBS and blocked with peroxidase block (DakoCytomation, Glostrup, Denmark) for 5 minutes. Slides then were incubated with the primary antibody as follows: PGC-1> (1:100; rabbit), NRF-1 (1:100; rabbit), mnSOD (1:500; rabbit), SMI32 (1:100; Sternberger Monoclonal, Baltimore, MD, mouse) diluted in blocking solution (5% nonfat dry milk [Sucofin] in TBS with 0.3% Triton X-100 [Sigma-Aldrich, Steinheim, Germany]) overnight at 4-C. Secondary antibody Alexa Fluor 555 goat anti-rabbit IgG (H + L) (1:50; Invitrogen) or Alexa Fluor 488 goat anti-mouse IgG (H + L) (1:50; Invitrogen) in blocking solution was added for 45 minutes. Slides were covered with Mowiol (Calbiochem). The staining was analyzed by using an Olympus BX61 microscope equipped with an Olympus DP72 digital camera (Olympus, Hamburg, Germany).
Glial fibrillary acidic protein (GFAP) staining in human spinal cord tissue was performed as previously described (36) . Slides were washed in PBS with 1 mmol/L Tris-HCl and blocked with peroxidase block (DakoCytomation) for 10 minutes and for 1 hour with 5% goat serum in PBS with 0.3% Triton X-100 (Sigma-Aldrich). Slides then were incubated with the primary antibody specific for GFAP (1:4000; polyclonal rabbit anti-GFAP; DakoCytomation) diluted in 1% goat serum in PBS with 0.006% Triton X-100 overnight at 4-C. Secondary anti-rabbit HRP antibody (EnVision + System-HRP [AEC]; DakoCytomation) was added for 30 minutes, followed by 20-minute incubation in chromogen substrate (EnVision + System-HRP [AEC]; DakoCytomation). Slides were covered with Dako Faramount (DakoCytomation).
For PGC-1>/DAB staining (rabbit, 1:100; Calbiochem) in human spinal cord tissue, we used the same protocol as for GFAP staining, with DAB (SK-4100; Vector Laboratories, Burlingame, CA) as chromogen. Hematoxylin and eosin (H&E) staining was done in adjacent human spinal cord sections and in muscle sections from the same tissue blocks that were used for immunohistochemistry, qPCR, and Western blot analyses.
Motoneuron numbers were quantified in Nissl-stained human and mouse spinal cord sections also adjacent to the regions used for immunohistochemistry, qPCR, and Western blot (36) .
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). Data were expressed as mean T SEM, and significance level was set as p G 0.05. Results were compared after testing for normal distribution by either Student t-test or Mann-Whitney U test.
RESULTS
Diminished mRNA and Protein Expression of PGC-1> and PGC-1>-Regulated Factors in SOD1
G93A ALS Mice
We detected significant reductions of PGC-1>, Tfam, and mnSOD mRNA levels in spinal cord of SOD1
G93A transgenic mice at disease end stage (Fig. 1A) . In muscle tissue, mRNA expression of PGC-1>, NRF-1, Tfam, and mnSOD mRNA was significantly already reduced at the presymptomatic stage (Day 40) (Fig. 1B) . Nonsignificant trends toward reduced AChR? and Utrn expression were also seen in muscle of SOD1 G93A ALS mice at the presymptomatic disease stage. At the early symptomatic stage (Day 90), PGC-1> and Utrn mRNA expression was significantly reduced in SOD1 G93A muscle tissue. At the end stage, we found a significant reduction of PGC-1>, NRF-1, Tfam, and mnSOD mRNA in SOD1 G93A ALS mouse muscle (Fig. 1B) . No alterations in mRNA expression of PGC-1>, NRF-1, NRF-2, and Tfam between SOD1 G93A ALS and nontransgenic mice were detected before or after disease onset in brown fat tissue (data not shown).
By Western blot analyses, we found significant reductions of PGC-1> protein levels in spinal cord tissue at the presymptomatic stage (Day 40) (Fig. 1C) . At the early symptomatic stage, there was a nonsignificant trend toward decreased PGC-1> and NRF-1 levels in SOD1 G93A ALS mouse spinal cord. Both PGC-1> and NRF-1 were significantly reduced in disease end stage in SOD1 G93A ALS animals. Western blots of muscle homogenates showed nonsignificant trends toward reduced PGC-1>, mnSOD, and AChR? expression at the presymptomatic stage (Day 40) and toward reduced NRF-1 and AChR? expression at the early symptomatic stage (Fig. 1D) . A significant reduction of NRF-1 was detected by Western blot in muscle tissue at the disease end stage; mnSOD and AChR? expressions were not significantly diminished. Western blot analysis did not reveal expression differences in PGC-1>, NRF-1, NRF-2, or Tfam proteins between SOD1 G93A ALS and nontransgenic mice at any time point in brown fat tissue (data not shown).
Consistent with qRT-PCR analyses, immunohistochemical staining of PGC-1>, NRF-1, and mnSOD double-stained with SMI32 showed a more pronounced expression in tissue of nontransgenic compared with end-stage SOD1 G93A ALS mice. This difference was most obvious in muscle tissue. In spinal cord tissue, a predominantly neuronal expression of PGC-1>, NRF-1, and mnSOD was observed (Fig. 2) 
Diminished mRNA and Protein Expression of PGC-1> and PGC-1>-Regulated Factors in ALS Patients
We found downregulated mRNA levels of PGC-1> and the PGC-1>Yregulated factors NRF-1, NRF-2, and Tfam in human postmortem ALS spinal cord (Fig. 3A) and motor cortex (Fig. 3C) ; mnSOD mRNA was also significantly reduced in ALS motor cortex tissue. The mRNA expression of PGC-1>, NRF-1, NRF-2, and Utrn was decreased in muscle biopsy specimens from ALS patients, and there was a tendency toward decreased expression of mnSOD and AChR? (Fig. 3E) .
Western blot analyses showed a significant reduction of Tfam protein expression in ALS postmortem spinal cord tissue (Fig. 3B) . Nonsignificant decreases were further observed for PGC-1> and mnSOD. In the motor cortex, there was a significant reduction of Tfam, and NRF-1 and mnSOD (Fig. 3D) were also reduced. Decreased expression was found for NRF-1 and Tfam in ALS muscle biopsy specimens (Fig. 3F) .
Immunohistochemistry in human spinal cord tissue revealed neuronal origin of PGC-1>, NRF-1, and mnSOD; double staining with SMI-32 showed expression in motoneurons. Immunostaining was less intense in tissue of ALS patients compared with controls both in double immunofluorescence staining (Fig. 4A ) and in serial spinal cord sections with PGC-1>-/DAB immunostaining and H&E staining (Fig. 4B) . Similar to the results in SOD1 G93A mice, the difference was most pronounced in muscle tissue (Fig. 4A) . The H&E stainings of human ALS and control muscle tissue sections from the same muscle are shown in Figure, Whereas immunohistochemistry showed a reduced signal intensity of PGC-1>, NRF-1, and mnSOD in human ALS and SOD1 G93A mouse spinal cord and muscle, Western blot analysis was only significant for PGC-1> and NRF-1 in mouse spinal cord and for NRF-1 in mouse muscle. These discrepancies were in part caused by high SDs mainly in human material and overall comparatively weak Western blot signals for PGC-1> and NRF-1, which may have impaired adequate quantification. They might further be explained for the spinal cord by the fact that Western blot analyses were done in whole tissue homogenates and, therefore, do not specifically reflect changes in the ventral horn.
SOD1
G93A ALS mice and in human ALS. Reduced mRNA expression levels of PGC-1>, NRF-1, NRF-2, and Tfam have been reported in hippocampi of Alzheimer disease patients (37) . The PGC-1> transcription impairment in the striatum (20) and a significant decrease of PGC-1> and PGC-1A but unchanged NRF-1 and Tfam mRNA expression in muscle tissue have been reported in HD patients (21) . Moreover, the gene coding for PGC-1> has been identified as a disease modifier in HD (38, 39) . In a mouse model of HD, decreased mRNA expression of PGC-1> and Tfam in muscle tissue correlated with reduced numbers of mitochondria, whereas PGC-1A, NRF-1, and further downstream target genes were not significantly reduced. (21) . These observations have led to the suggestion that the progressive muscle atrophy and morphologic abnormalities of neuromuscular junctions that occur in HD mice could be a consequence of impaired PGC-1> and target gene expression (21) .
Studies in ALS transgenic mice revealed protective effects of PGC-1> and peroxisome proliferatorsYactivated receptor-F agonists (23, 24, 26) . Muscle-specific PGC-1> upregulation in ALS mice led to improved mitochondrial biogenesis and muscle function but did not prolong the survival (26) . Assessment of double-transgenic animals overexpressing both the SOD1 G93A mutation and human PGC-1> revealed protective effects of PGC-1> overexpression on motoneuron loss (23) . Our finding that PGC-1>, NRF-1, and mnSOD are mainly localized in neurons suggests that these protective effects are of neuronal rather than glial origin.
Mitochondria are likely involved in the pathogenesis of both sporadic and mutant SOD1Yrelated familial ALS (5, 8Y12, 40, 41) . Impaired function or expression of PGC-1> could induce neurodegeneration by subsequent deficits in mitochondrial gene expression and resulting changes in energy metabolism. Our present data support the suggestion that mitochondria could be primary targets for mutant SOD1-mediated damage but also in nonmutant SOD1-related human ALS patients (5) . The PGC-1> plays a role in adaptive thermogenesis in brown fat tissue by coactivating the expression of uncoupling protein 1, the expression of which is restricted to mitochondria of brown fat tissue. In contrast to HD transgenic mice (which display profound thermoregulatory defects and abnormal brown fat tissue because of disruption of the PGC-1>Yuncoupling protein 1 circuit), we could not detect changes in the expression of PGC-1> or one of the downstream factors in brown adipose tissue of SOD1 G93A ALS mice. Because ALS is associated with several defects in energy metabolism, including weight loss, hypermetabolism, and hyperlipidemia (42, 43) , muscle mitochondrial defects might lead to hyperlipidemia and impaired energy expenditure (44) . Decreased expression of PGC-1>, Tfam, and NRF-1 in muscle tissue would likely contribute to these metabolic abnormalities. In addition to its direct effects on mitochondrial gene expression, PGC-1> is also involved in the regulation of genes of the ROS defense system, including the ROS-detoxifying enzyme mnSOD. It is unclear whether oxidative stress is a primary or a secondary cause of neurodegeneration in ALS, but data from both human tissue and transgenic animal models suggest that it is a major contributory factor leading to motor neuron death (45) . Previous studies on mnSOD expression in ALS have been controversial, that is, increases in expression levels of mnSOD in astrocytes in spinal cord and motor cortex of ALS patients were detected by immunohistochemistry (46Y48), but no changes in protein levels and enzyme activity were seen in the motor cortex (47, 49) . Decreased mnSOD expression in ALS skeletal muscle has also been previously reported (8) . In SOD1 G93A transgenic mice, reduction of mnSOD worsened the ALS-like phenotype, whereas mnSOD overexpression was protective against neuronal toxicity induced by adenovirus-mediated expression of mutant SOD1 G93A (50) . Moreover, mnSOD was upregulated in PGC-1>/mutant SOD1 G37R double-transgenic animals at all disease stages (26) . In addition, Tfam was also recently shown to delay onset of disease, prevent motoneuron loss, and reduce oxidative stress in motoneurons in double-transgenic mice overexpressing G93A mutant SOD1 and human Tfam (51). Several studies suggest that mitochondrial abnormalities occur long before disease onset (52) . In the present study, mRNA expression changes in the spinal cord of ALS animals increased with disease progression and were most prominent at the end stage. It could be argued that reduced expression levels of PGC-1> and PGC-1>Yregulated factors in human ALS brain and spinal cord as well as in mouse spinal cord might at least in part be caused by neuronal loss and not necessarily contribute to the origin of neurodegeneration in ALS. On the other hand, in skeletal muscle tissue, a reduction of PGC-1>, NRF-1, Tfam, and mnSOD mRNA expression was found before disease onset in SOD1 G93A ALS mice and in patients who subsequently were confirmed to have ALS (Table) . These patients represent less advanced disease stages in comparison with postmortem brain and spinal cord tissue of patients who had died of ALS. This is of particular interest because there is evidence that degeneration of motor end plates occurs before the loss of motoneuron cell somata in the spinal cord and that neurodegeneration in ALS is a dyingback process that begins in the muscle (28Y30). Therefore, we postulate that the abnormalities in PGC-1>Yrelated mitochondrial gene transcription in early disease may contribute to muscular and distal axonal pathology.
The PGC-1> also regulates the neuromuscular junction gene program via coactivation of NRF-2 in skeletal muscle. However, our present data on numbers of AChR clusters do not support a specific correlation between PGC-1> reduction and changes in expression of AChR and Utrn.
In conclusion, we provide evidence for a role of PGC-1> and PGC-1>Yregulated factors in mitochondrial dysfunction and impaired antioxidant defense both in the ALS mouse model and in human sporadic ALS. Although our findings in spinal cord of SOD1 G93A ALS mice and in spinal cord and motor cortex of human sporadic ALS might be attributed at least in part to neuronal loss in advanced stages, the findings in skeletal muscle of SOD1 G93A ALS mice and ALS patients suggest an early decrease in PGC-1>Yregulated mitochondrial function. Further studies will need to extend these analyses to other ALS animal models to understand whether decreases in PGC-1> and PGC-1>Yregulated genes are common pathogenetic mechanisms. Activation or overexpression of PGC-1> could then become a useful approach to compensate for mitochondrial loss and dysfunction and to counteract oxidative stress, thereby providing protection against neurodegeneration in ALS patients.
